Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
Suqin He(Shanxi Agricultural University), David A. Proia(C4 Therapeutics (United States))
Cited by 60
Related Papers
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
|Investigational New Drugs|2012|79
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
|Investigational New Drugs|2014|73
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
|Investigational New Drugs|2013|58